ABT 538

Known as: ABT-538, ABT538 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2011
05101519952011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
To understand the underlying mechanisms of significant differences in dissociation rate constant among different inhibitors for… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2002
2002
Kinetic characterization and cross resistance pattern studies of HIV-1 aspartic protase (PR) inhibitors have shown that some… (More)
Is this relevant?
1997
1997
The metabolism and disposition of [14C]ritonavir (ABT-538, NOR-VIR), a potent, orally active HIV-1 protease inhibitor, were… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
1996
Highly Cited
1996
The HIV-1 protease inhibitor ritonavir (ABT-538) undergoes cytochrome P450-mediated biotransformation in human liver microsomes… (More)
Is this relevant?
1996
1996
OBJECTIVE To define genotypic and phenotypic resistance patterns following prolonged therapy with the protease inhibitor… (More)
Is this relevant?
1996
1996
Mutations in the human immunodeficiency virus (HIV) protease (L90M, G48V, and L90M/G48V) arise when HIV is passaged in the… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Treatment of infected patients with ABT-538, an inhibitor of the protease of human immuno-deficiency virus type 1 (HIV-1), causes… (More)
Is this relevant?
1995
1995
Inhibitors of the human immunodeficiency virus protease represent a promising new class of antiretroviral drugs for the treatment… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1995
1995
  • Positively aware : the monthly journal of the…
  • 1995
ABT-538, a new protease inhibitor, appears to increase CD4 counts and viral load in HIV-infected persons. In a four-week placebo… (More)
Is this relevant?